Lars Wagner named next CEO of Airbus’ commercial aircraft division

Christian Scherer   Chief Executive Officer of the Commercial Aircraft business Airbus Airbus SE
Christian Scherer Chief Executive Officer of the Commercial Aircraft business Airbus - Airbus SE
0Comments

Lars Wagner is set to take over as the Chief Executive Officer of Airbus’ Commercial Aircraft business starting January 1, 2026. Currently serving as CEO of MTU Aero Engines AG in Munich, Wagner will join the Airbus Executive Committee. He will replace Christian Scherer, who has been in various executive roles at Airbus for over four decades.

Wagner will begin his transition to Airbus in November 2025 to ensure a seamless handover from Scherer. At MTU Aero Engines AG, Wagner has served as CEO since January 2023 and has held significant roles such as Chief Operating Officer and Executive Vice President for OEM operations since joining the company in 2015. His career also includes management positions at Airbus facilities in Bremen, Hamburg, and Toulouse. Wagner holds degrees in mechanical and aeronautical engineering and an MBA.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.